Icon has become the first contract research company to help manage the reams of big data coming from the U.K.'s unique private-public partnership Genomics England.
CRO giant Icon has expanded its technology portfolio with a system it says can improve patient randomization and clinical supply in adaptive trials.
Global CRO Icon bought a U.S.-based network of clinical research sites, expanding its stateside footprint and bringing in a trove of patient data the company believes will help it to improve study design.
CRO giant Icon is looking to expand its share of the drug development market in Asia, hiring a pair of local veterans to deepen its ties to the region.
Irish-headquartered CRO Icon kept its streak of quarterly revenue growth running, posting a 1.8% year-over-year increase in sales.
CRO giant Icon is working with IBM in hopes of making clinical trials more efficient, tapping the company's famed Watson technology with an eye on speeding up recruitment and site selection.
Irish CRO Icon has signed on to be the exclusive service provider for a new U.K. biotech startup, planning to help the nascent company advance a trio of Novartis-developed drugs.
Icon is again reducing its revenue expectations for 2015 but increasing its profit guidance, counting on a big quarter of business wins to balance some sluggish backlog conversion.
CROs Icon and Covance signed a pair of separate partnerships in the world of cancer diagnostics, each betting that new technologies in oncology testing will increase global demand.
Icon, at work on new approaches to educating potential study participants, launched a new technology designed to inform patients of the possible risks and benefits of a clinical trial before they meet with a physician.